DDInter1729 DDInter1492
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Sulindac {u} (Compound) causes {v} (Side Effect) Hypertension
Hypertension {u} (Side Effect) is caused by {v} (Compound) Ponatinib
Sulindac {u} (Compound) causes {v} (Side Effect) Hypertension
Hypertension {u} (Side Effect) is caused by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Sulindac {u} (Compound) causes {v} (Side Effect) Dermatitis exfoliative
Dermatitis exfoliative {u} (Side Effect) is caused by {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ponatinib
Sulindac {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Sulindac {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Ranitidine
Ranitidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ponatinib
Sulindac {u} (Compound) binds {v} (Gene) PTGDR2
PTGDR2 {u} (Gene) is bound by {v} (Compound) Indomethacin
Indomethacin {u} may lead to a major life threatening interaction when taken with {v} Ponatinib
Sulindac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is regulated by {v} (Gene) BCR
BCR {u} (Gene) is bound by {v} (Compound) Ponatinib
Sulindac {u} (Compound) binds {v} (Gene) AKR1B1
AKR1B1 {u} (Gene) regulates {v} (Gene) PGAM1
PGAM1 {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Sulindac {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) interacts with {v} (Gene) SACS
SACS {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Sulindac {u} (Compound) binds {v} (Gene) AKR1B1
AKR1B1 {u} (Gene) regulates {v} (Gene) TESK1
TESK1 {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Sulindac (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Ponatinib (Compound)
Sulindac (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Sulindac (Compound) causes Dermatitis exfoliative (Side Effect) and Dermatitis exfoliative (Side Effect) is caused by Lansoprazole (Compound) and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Sulindac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Sulindac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Ranitidine (Compound) and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Sulindac (Compound) binds PTGDR2 (Gene) and PTGDR2 (Gene) is bound by Indomethacin (Compound) and Indomethacin may lead to a major life threatening interaction when taken with Ponatinib
Sulindac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is regulated by BCR (Gene) and BCR (Gene) is bound by Ponatinib (Compound)
Sulindac (Compound) binds AKR1B1 (Gene) and AKR1B1 (Gene) regulates PGAM1 (Gene) and PGAM1 (Gene) is downregulated by Ponatinib (Compound)
Sulindac (Compound) binds ALB (Gene) and ALB (Gene) interacts with SACS (Gene) and SACS (Gene) is downregulated by Ponatinib (Compound)
Sulindac (Compound) binds AKR1B1 (Gene) and AKR1B1 (Gene) regulates TESK1 (Gene) and TESK1 (Gene) is upregulated by Ponatinib (Compound)